Thymosin beta-4 (Tβ4) is a highly conserved, naturally occurring water-soluble peptide present in all tissues and cell types except red blood cells. This peptide plays a critical role in tissue regeneration by binding to actin and facilitating cell migration. Tβ4 is known to promote the mobilization, migration, and differentiation of stem and progenitor cells, support the formation of new blood vessels (angiogenesis), and enhance tissue repair. Additionally, Tβ4 reduces the number of myofibroblasts in wounds, thereby minimizing scar formation and fibrosis.

The therapeutic potential of Tβ4 has been widely explored. A 2020 review by Geir Bjørklund and colleagues highlighted its promising role in cardiac healing, including its capacity to stimulate tissue repair in heart injuries (1). Other areas of research on Tβ4 include its application in the treatment of dry eye syndrome, diabetes, and pressure ulcers (also known as bedsores).

Currently, Björklund Pharma AS is actively evaluating the therapeutic and commercial potential of Tβ4, focusing on leveraging its multi-faceted regenerative properties to drive innovative medical treatments and address unmet needs in high-impact therapeutic areas. The company aims to position Tβ4 as a first-in-class solution for conditions where existing treatments are limited or ineffective, creating significant opportunities for market leadership and investor growth.

Reference

1. Bjørklund G, Dadar M, Aaseth J, Chirumbolo S. Thymosin β4: a multi-faceted tissue repair stimulating protein in heart injury. Curr Med Chem 2020; 27(37): 6294-6305.